Anadys Pharmaceuticals study confirms safety of ANA975 for the treatment of hepatitis C

By Angela McDaniels

Seattle, Nov. 14 - Anadys Pharmaceuticals Inc. said a phase 1 clinical trial showed its isatoribine prodrug ANA975 for the treatment of hepatitis C to be safe and well tolerated.

The clinical trial was conducted in the United Kingdom and included 36 healthy volunteers who each received a single, oral dose of ANA975 of either 400 milligram, 800 milligrams or 1200 milligrams.

ANA975 also reduced plasma isatoribine exposures, the company said.

The data was presented at a poster session on Monday at the American Association of the

Study of Liver Diseases annual meeting in San Francisco.

In an earlier proof-of-concept clinical study, an intravenous infusion of 800 mg of isatoribine once a day for seven days to patients chronically infected with hepatitis C virus yielded a significant reduction in viral levels, the company said.

Anadys is developing ANA975 in collaboration with Novartis for chronic hepatitis C virus as well as potentially other infectious disease indications.

Novartis is a pharmaceutical company based in Basel, Switzerland.

Anadys Pharmaceuticals is a San Diego-based biopharmaceutical company that develops small-molecule medicines for the treatment of hepatitis C virus, hepatitis B virus and other serious infections.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.